Review

Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer. E.S. WENZEL, A.T.K. SINGH (Kenosha, WI, USA) ............................................................................................................................... 1

Experimental Studies

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (Utrecht, the Netherlands; Cambridge, UK) ........................................................................................... 7

Effects of 2,3-Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (Yokohama, Japan) .......................................................... 19

EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer. K. MASUDO, N. SUGANUMA, H. NAKAYAMA, T. OSHIMA, Y. RINO, H. IWASAKI, K. MATSUZU, K. SUGINO, K. ITO, T. KONDO, Y. NAKAMURA, M. YOSHIIHARA, M. MASUDA, Y. MIYAGI (Yokohama; Tokyo; Yamanashi, Japan) ........................................................................................................... 25

Effect of Benifuuki Tea on Cytochrome P450-mediated Metabolic Activity in Rats. T. HIRAI, Y. NISHIMURA, N. KURATA, H. NAMBA, M. IWASE, Y. GOMI, H. TSUCHIYA, T. YAMAKAWA, Y. KIUCHI (Tokyo; Fujiyoshida, Japan) ........................................................................................................... 33


Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-based Case–control Study. Y.-R. LEE, N. TIEN, C.-L. LIN, H.-Y. SHEN, D.-T. BAU, Y.-P. LIM (Chiayi; Taichung, Taiwan, ROC) ....................................................................................................................... 47

Contents continued on the back cover
Editorial Board

I. ABRAHAM, The HOPE Center, University of Arizona, Tucson, AZ, USA
N.J. AGNANTIS, Department of Pathology, University of Ioannina, Ioannina, Greece
D. ANDERSON, Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK
V. BARAK, Department of Oncology, Hadassah University Hospital, Jerusalem, Israel
M.H. BARCELLOS-HOFF, Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
K. BEIER, Department of Histology, University of Basel, Basel, Switzerland
M. BERGQVIST, Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden
R. BJERKVIG, Nordlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway
W. BOWNE, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA
M. CARAGLIA, Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy
P. CHANDRA, Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany
J.-G. CHUNG, Department of Medicine, China Medical College, Taichung, Taiwan, ROC
L.A. COHEN, Northampton, MA, USA
A.I. CONSTANTINOU, Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus
T. DALIANIS, Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden
G. DELCONSTANTINOS, Department of Experimental Physiology, University of Athens Medical School, Athens, Greece
D.T. DENHARDT, Division of Life Sciences, Rutgers University, Bridgewater, NJ, USA
W. DEN OTTER, VUMC - Department of Urology, Amsterdam, The Netherlands
K. DE MEIRLEIR, Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium
L. DE RIDDER, Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium
E.P. DIAMANDIS, Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada
J.M. DRAKE, Division of Medical Oncology, RBHS-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
T. EFFERTH, Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany
W. ENGSTRÖM, Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
M. ESKELINEN, Department of Surgery, University Hospital of Kuopio, Kuopio, Finland
J.A. FERNANDEZ-POL, Metalloproteomics, LLC, Chesterfield, MO, USA
G. FIORENTINI, UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy
P.B. FISHER, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA
I. FREITAS, Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy
M. FRIEDRICH, Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany
R.E. FRIEDRICH, Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany
R. GANAPATHI, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
G. GITSCH, Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany
V. GORGOULIS, Department of Histology-Embryology, Medical School, University of Athens, Greece
J.S. GREENBERGER, Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA
J.W. GREINER, National Cancer Institute, NIH, Bethesda, MD, USA
D.S. GRIDLEY, Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA
C.J. GRUBBS, Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA

continued
D. RADES, Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
F.M. ROBERTSON, Virginia Commonwealth University, Clinical Research Services, Center for Clinical and Translational Research, Richmond Academy of Medicine, Richmond, VA, USA
D. RUBELLO, Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy
C.A. RUBIO, Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden
G.R. RUTTEMAN, Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands
H. SAKAGAMI, Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan
G. SAVA, Institutes of Biological Research, Fondazione Cellerio-Onlus, Trieste, Italy
D. SCHIFFER, Neuro-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy
L.D. SHULTZ, The Jackson Laboratory, Bar Harbor, ME, USA
G. SICA, Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy
J.M. SIEGFRIED, Department of Pharmacology, MNPI Center, University of Minnesota, Minneapolis, MN, USA
J. SLANSKY, Integrated Department of Immunology, School of Medicine, University of Colorado Denver and National Jewish Health, Denver, CO, USA
R.M. SNAPKA, Department of Radiology, The Ohio State University, Columbus, OH, USA
G.-I. SOMA, Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
P.P. SORDILLO, Department of Medical Oncology and Hematology, Lenox Hill Hospital, New York, NY, USA
T.A. SPRINGER, Department of Pathology, Harvard Medical School, Boston, MA, USA
D.D. SPYROPOULOS, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA
K. SYRJÄNEN, Biohit Healthcare Oyj, Helsinki, Finland
G.C. TORRE, Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy
B. TRIBUKAIT, Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden
J. VADGAMA, Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA
J.K. VISHWANATHA, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA
W. WANG, Research Institute of Healthcare Science, University of Wolverhampton, UK
N. WATANABE, Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
W. WEBER, Clinical Cancer Etiology Unit, Basel, Switzerland
L.M. WEINER, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
J.A. WERNER, Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany
S. YLÄ-HERTTUALA, Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland
H. YOSHIDA, Department of Pathology, Kagoshima University, Kagoshima, Japan
Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 31, 2017.

A. Alfred Taubman Medical Research Institute, Ann Arbor, MI, U.S.A.
Aarhus University Hospital, European Neuroendocrine Tumor Society (ENETS) Centre of Excellence, Aarhus, Denmark
Animal Facility, University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, PA, U.S.A.
Assisted Reproduction Unit, Attikon University Hospital, Athens, Greece

Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Bekzamek Yavfi University, Istanbul, Turkey
Bildungsministerium für Bildung und Forschung (BMBF), Berlin, Germany
Bio-industry Technology Development Program, Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry & Fisheries, Anyang, Republic of Korea
Bio-oriented Technology Research Advancement Institution (BRAIN), National Agriculture and Food Research Organization (NARO), Japan
BK21 Program for Veterinary Science, Seoul National University, Seoul, Republic of Korea
Bower Foundation, Ridgeland, MS, U.S.A.

Center for Molecular Imaging and the Tumor Imaging Core, Department of Radiology, University of Michigan, Ann Arbor, MI, U.S.A.
Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
Chosun University, Gwangju, Republic of Korea
Chugai Pharmaceutical Co., Ltd, Tokyo, Japan
Clinical Medicine Research Institute, Chosun University Hospital, Gwangju, Republic of Korea
Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
Council for Science, Technology and Innovation (CSTI), Tokyo, Japan
Cross-ministerial Strategic Innovation Promotion Program (SIP), Japan

Department of Aging Regulation, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Department of Hematology, KEM Hospital, Mumbai, India
Department of Histology-Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Department of Molecular Target Medicine Screening, Aichi Medical University School of Medicine, Aichi, Japan
Department of Pathology, University Clinical Centre Maribor, Maribor, Slovenia
Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, U.S.A.
Deutsches Zentrum für Herz-Kreislau-Forschung (DZHK), Berlin, Germany
Diabetic Nephropathy Treatment Study Group, Japan
Edanz Group, Tokyo, Japan
Editage, Tokyo, Japan
Enago, Tokyo, Japan
Eskisehir Osmangazi University, Eskisehir, Turkey

Faculty Hospital Plzen, Pilsen, Czech Republic
Fanconia Anemia Research Fund, Eugene, OR, U.S.A.
Frankel Cardiovascular Center, Ann Arbor, MI, U.S.A.
Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal

Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
Grants-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology(MEXT) of Japan, Tokyo, Japan

Hallym University, Chuncheon, Republic of Korea
Hangzhou Health Science and Technology Fund, Zhejiang Province, P.R. China
Harold Amos Medical Faculty Development Program, Indianapolis, IN, U.S.A.
Hellenic Endocrine Society, Athens, Greece
Hirosaki Chuo Hospital, Hirosaki, Japan
Hirosaki University Graduate School of Medicine, Hirosaki, Japan

Imamura Clinic, Kagoshima, Japan
Indian Council of Medical Research, New Delhi, India
Industrial Technology Innovation Program, Ministry of Trade, Industry & Energy, Sejong, Republic of Korea
Ipsen, Paris, France
Isukaiichi Naika Clinic, Isukaiichi, Japan
Japan Society for the Promotion of Science(JSPS), Tokyo, Japan

Kanagawa Cancer Center, Yokohama, Japan
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C.
Kensei Hospital, Tokyo, Japan
Kitasato University Medical Center, Kitamoto, Japan
Latvia, Lithuania and Taiwan Cooperation Project
Maxwell International, Inc, Chiba, Japan
Medical Research Core Facilities Center, Office of Research & Development, China Medical University, Taichung, Taiwan, R.O.C.
Ministry of Human Capacities, Budapest, Hungary
Ministry of Science and Higher Education, Warsaw, Poland
Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea
Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
National Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, U.S.A.
National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A.
National Sustainability Program I (NPU I), Ministry of Education Youth and Sports of the Czech Republic, Prague, Czech Republic
Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea
Novartis International AG, Basel, Switzerland
Novo Nordic Foundation, Bagsvaerd, Denmark
Physiology Phenotyping Core (PPC), University of Michigan, Ann Arbor, MI, U.S.A.
Postdoc Fellowships of Excellence – Siemens, State Scholarships Foundation (IKY), Athens, Greece
Programa Operacional Competitividade e Internacionalização (POCI), COMPETE2020, Lisboa, Portugal
Programa Operacional Factores de Competitividade and the European Union (FEDER), COMPETE2020, Lisboa, Portugal
Research Agency, Republic of Slovenia
Research Council (CNCS)- Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
Research Council of Lithuania, Lithuania
Research Grant for Young Researchers, Kitasato University, Tokyo, Japan
Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea
Research Project of Charles University, Prague, Czech Republic
Rigshospitalet, Denmark
Robert Wood Johnson Foundation (RWJF), Princeton, NJ, U.S.A.
Saiseikai Nakatsu Hospital, Osaka, Japan
Scientific Communication srl., Naples, Italy
Section of Pediatric Surgery, University of Michigan, Ann Arbor, MI, U.S.A.
State Serum Institute, Denmark
Stem Cell Research Center, K-STEMCELL Co., Ltd, Seoul, Republic of Korea
Stiftungsfonds BIXO, Germany
Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
Takeda Science Foundation, Japan
Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C.
THORAX Research Center for Intensive and Emergency Thoracic Medicine, Athens, Greece
Tissue-bank of China Medical University Hospital, Taichung, Taiwan, R.O.C.
Tsugaru General Hospital, Goshogawara, Japan
Tumour and Angiogenesis Research Group, Greece
University of Pécs, Pécs, Hungary
Vevo 2100 Imaging System, FUJIFILM VisualSonics, Inc., Toronto, ON, Canada
Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Wilhelm-Sander-Foundation, Munich, Germany
Instructions for Authors 2018

**General Policy.** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

**Open Access Policy.** IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 575.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 58.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

**Copyright.** Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

**Ethical Policies and Standards.** IN VIVO agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

**Specific information and additional instructions for Authors**

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

5. Authors should pay attention to the following points when writing an article for IN VIVO:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

8. Articles submitted to IN VIVO may be rejected without review if:

- they do not fall within the journal’s policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to IV.
- plagiarism is detected by plagiarism screening services.
- (Rejection rate (2016): 59%).

9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.

11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).
Review